Lv5
1200 积分 2024-07-24 加入
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations
3天前
已完结
P-Loop/αC-Helix Compressing Mutations and Exon 20 Insertions in EGFR-Mutant NSCLC: A Rapidly Evolving Therapeutic Landscape
19天前
已关闭
Rethinking survival metrics in EGFR-mutated NSCLC: insights from RMST analysis of FLAURA2 and MARIPOSA
1个月前
已完结
Is There Still Room for Monotherapy in EGFR-Mutated Non-Small Cell Lung Cancer?
1个月前
已完结
First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial
1个月前
已完结
Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non–Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834
1个月前
已完结
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial
1个月前
已关闭
Aumolertinib with or without chemotherapy in EGFR-mutated advanced non-small-cell lung cancer (AENEAS2): an open-label, multicentre, randomised, controlled, phase 3 trial
1个月前
已完结
Does OptiTROP-Lung05 open a new frontier for first-line ADC-ICI combinations in NSCLC?
2个月前
已完结
Expert consensus on the clinical application of TROP2-targeted antibody-drug conjugates in non-small cell lung cancer (2026 edition)
2个月前
已完结
皖公网安备34019202002308
